Cointime

Salient Pharmaceuticals

company

About

Salient is developing CASAD™, a proprietary composition proven to adsorb a range of toxins and inflammatory proteins.

  • 1 - 10

Highlights

Total Funding Amount
$2M
Funding Rounds
1
Investors
1

Details

Last Funding Type
Series Unknown
Last Funding Money Raised
$2M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2007
Number Of Employee
1 - 10
Operating Status
Active

Salient is a Texas-based company formed in 2007 to explore the pharmaceutical application of its proprietary composition of a rare, all-natural mineral. This composition has been proven to adsorb a range of toxins and inflammatory proteins commonly associated with diarrhea.

Salient’s compound, CASAD™, is envisioned to be a “platform” product effective across a spectrum of conditions from Cancer Therapy-Induced Diarrhea to infectious disease and chronic GI conditions. It also has the potential to be used as a rescue agent for other drugs with toxic side effects.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$2M
Salient Pharmaceuticals has raised a total of $2M in funding over 2 rounds. Their latest funding was raised on Jan 29, 2010 from a Series Unknown round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 29, 2010 Series Unknown $2M 1 Texas Wide Open for Business — Detail

Investors

Number of Lead Investors
Number of Investors
1
1
Salient Pharmaceuticals is funded by 1 investors. Texas Wide Open for Business are the most recent investors.
Investor Name Lead Investor Funding Round
Texas Wide Open for Business Yes Series Unknown
Cointime
İçerikler
Şirket.